A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells

Kun Zhou, Kevin W Diebel, Jon M Holy, Andrew J Skildum, Evan Odean, Douglas A. Hicks, Brent Schotl, Juan E Abrahante - Llorens, Monique A. Spillman, Lynne T Bemis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events. One such tRF, a 5' fragment of tRNA-Glu-CTC (tRF5-Glu), is processed from the mature tRNA-Glu and is shown in this study to be expressed in ovarian cancer cells. We confirmed that tRF5- Glu binds directly to a site in the 3'UTR of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) mRNA thereby down regulating its expression. BCAR3 has not previously been studied in ovarian cancer cells and our studies demonstrate that inhibiting BCAR3 expression suppresses ovarian cancer cell proliferation. Furthermore, mimics of tRF5-Glu were found to inhibit proliferation of ovarian cancer cells. In summary, BCAR3 and tRF5-Glu contribute to the complex tumor heterogeneity of ovarian cancer cells and may provide new targets for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)95377-95391
Number of pages15
JournalOncotarget
Volume8
Issue number56
DOIs
StatePublished - Jan 1 2017

Fingerprint

RNA, Transfer, Glu
Transfer RNA
Ovarian Neoplasms
Estrogens
Breast Neoplasms
High-Throughput Nucleotide Sequencing
Neoplasms
Untranslated RNA
3' Untranslated Regions
MicroRNAs
Cell Proliferation
Messenger RNA
Therapeutics

Keywords

  • BCAR3
  • Noncoding RNA
  • Ovarian cancer
  • TRF5-Glu
  • TRNA fragments

PubMed: MeSH publication types

  • Journal Article

Cite this

A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells. / Zhou, Kun; Diebel, Kevin W; Holy, Jon M; Skildum, Andrew J; Odean, Evan; Hicks, Douglas A.; Schotl, Brent; Abrahante - Llorens, Juan E; Spillman, Monique A.; Bemis, Lynne T.

In: Oncotarget, Vol. 8, No. 56, 01.01.2017, p. 95377-95391.

Research output: Contribution to journalArticle

@article{883dc714b2464531ba173217b00f0ca1,
title = "A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells",
abstract = "Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events. One such tRF, a 5' fragment of tRNA-Glu-CTC (tRF5-Glu), is processed from the mature tRNA-Glu and is shown in this study to be expressed in ovarian cancer cells. We confirmed that tRF5- Glu binds directly to a site in the 3'UTR of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) mRNA thereby down regulating its expression. BCAR3 has not previously been studied in ovarian cancer cells and our studies demonstrate that inhibiting BCAR3 expression suppresses ovarian cancer cell proliferation. Furthermore, mimics of tRF5-Glu were found to inhibit proliferation of ovarian cancer cells. In summary, BCAR3 and tRF5-Glu contribute to the complex tumor heterogeneity of ovarian cancer cells and may provide new targets for therapeutic intervention.",
keywords = "BCAR3, Noncoding RNA, Ovarian cancer, TRF5-Glu, TRNA fragments",
author = "Kun Zhou and Diebel, {Kevin W} and Holy, {Jon M} and Skildum, {Andrew J} and Evan Odean and Hicks, {Douglas A.} and Brent Schotl and {Abrahante - Llorens}, {Juan E} and Spillman, {Monique A.} and Bemis, {Lynne T}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20709",
language = "English (US)",
volume = "8",
pages = "95377--95391",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "56",

}

TY - JOUR

T1 - A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells

AU - Zhou, Kun

AU - Diebel, Kevin W

AU - Holy, Jon M

AU - Skildum, Andrew J

AU - Odean, Evan

AU - Hicks, Douglas A.

AU - Schotl, Brent

AU - Abrahante - Llorens, Juan E

AU - Spillman, Monique A.

AU - Bemis, Lynne T

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events. One such tRF, a 5' fragment of tRNA-Glu-CTC (tRF5-Glu), is processed from the mature tRNA-Glu and is shown in this study to be expressed in ovarian cancer cells. We confirmed that tRF5- Glu binds directly to a site in the 3'UTR of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) mRNA thereby down regulating its expression. BCAR3 has not previously been studied in ovarian cancer cells and our studies demonstrate that inhibiting BCAR3 expression suppresses ovarian cancer cell proliferation. Furthermore, mimics of tRF5-Glu were found to inhibit proliferation of ovarian cancer cells. In summary, BCAR3 and tRF5-Glu contribute to the complex tumor heterogeneity of ovarian cancer cells and may provide new targets for therapeutic intervention.

AB - Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events. One such tRF, a 5' fragment of tRNA-Glu-CTC (tRF5-Glu), is processed from the mature tRNA-Glu and is shown in this study to be expressed in ovarian cancer cells. We confirmed that tRF5- Glu binds directly to a site in the 3'UTR of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) mRNA thereby down regulating its expression. BCAR3 has not previously been studied in ovarian cancer cells and our studies demonstrate that inhibiting BCAR3 expression suppresses ovarian cancer cell proliferation. Furthermore, mimics of tRF5-Glu were found to inhibit proliferation of ovarian cancer cells. In summary, BCAR3 and tRF5-Glu contribute to the complex tumor heterogeneity of ovarian cancer cells and may provide new targets for therapeutic intervention.

KW - BCAR3

KW - Noncoding RNA

KW - Ovarian cancer

KW - TRF5-Glu

KW - TRNA fragments

UR - http://www.scopus.com/inward/record.url?scp=85033401833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033401833&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20709

DO - 10.18632/oncotarget.20709

M3 - Article

VL - 8

SP - 95377

EP - 95391

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 56

ER -